Suggested remit - To appraise the clinical and cost effectiveness of STG320 within its marketing authorisation for treating persistent allergic rhinitis caused by house dust mites.
Status Proposed
Process STA pre-2018
ID number 1278

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 November 2017 - 21 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
20 December 2017 The National Institute for Health and Care Excellence has been asked to consider an appraisal of allergic rhinitis (persistent, house dust mites) - STG320 ID1278. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. On receiving updated regulatory timing information from the company that markets STG320, NICE has agreed that holding a scoping workshop at this time would not be appropriate. Consequently the scoping workshop arranged for the 15 January 2018 will be cancelled and the consultation on the draft scope will not continue. The workshop and consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email on

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance